Yahoo Web Search

  1. Ad
    related to ELI LILLY AND COMPANY
  1. Edited Transcript of LLY earnings conference call or presentation 30-Jul-19 1:00pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceAug 02 1:42 AM

    White Eli Lilly and Company - Senior VP & President of Lilly Oncology * Daniel M. Skovronsky Eli Lilly and Company - Senior VP ...

  2. Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates

    Zacks via Yahoo FinanceAug 05 14:46 PM

    Shares of Aduro BioTech, Inc. ADRO were down around 3.6% on Friday after it announced second-quarter 2019 results on Aug 1. In fact, so far this year, the stock has plunged 48.9%, underperforming the industry's decrease of 1.8%.

  3. Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine

    Zacks via Yahoo FinanceJul 31 13:34 PM

    Amgen AMGN reported second-quarter 2019 earnings of $3.97 per share, which beat the Zacks Consensus Estimate of $3.58. Aimovig faces competition from other newly launched CGRP antibodies, Lilly’s LLY Emgality and Teva’s TEVA Ajovy.

  4. Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y

    Zacks via Yahoo FinanceJul 30 17:06 PM

    Incyte Corporation INCY reported strong results for the second quarter of 2019, wherein both earnings and sales comprehensively beat expectations. The company reported earnings ...

  5. Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study

    Zacks via Yahoo FinanceAug 14 13:24 PM

    Eli Lilly & Company LLY announced superiority of its plaque psoriasis drug Taltz over J&J’s JNJ new drug, Tremfya (guselkumab), in delivering total skin clearance at week ...

  6. What's in Store for Array BioPharma (ARRY) in Q4 Earnings?

    Zacks via Yahoo FinanceJul 29 14:12 PM

    Investor focus will be on any update that Array BioPharma Inc. ARRY provides about its acquisition by Pfizer PFE when it reports fourth-quarter fiscal 2019 results. Please note that Pfizer had ...

  7. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally given 10 months to review new drugs. If a drug is selected for priority review, the FDA is allotted six months to review the drug.

  8. and China resume trade talks in Beijing today, with Treasury Secretary Mnuchin and Trade Rep Lighthizer working to re-establish and/or resurrect a trade deal (as President ...

  9. The company reported Tymlos’ sales of $41 million, surpassing the Zacks Consensus Estimate by 0.64% and increasing from $22.6 million in the year-ago quarter. We remind investors ...

  10. CLDX incurred adjusted second-quarter 2019 loss (excluding gain on fair value re-measurement of contingent consideration) of 92 cents per share, narrower than the Zacks Consensus Estimate of ...

  1. Ads
    related to ELI LILLY AND COMPANY